Search clinical trials for: CC-223

Total 2332 results

University of Toronto

Completed

Dietary Approach to Stop Hypertension With Sodium (Na) Reduction for Chinese Canadians (DASHNa-CC)

Hypertension
BioNTech SE
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

COVID-19 | Influenza, Human

United States
University of Florence

Active, not recruiting

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients (FLO_CC-486-)

MDS | CMML

Italy
Kirby Institute
Celgene

Active, not recruiting

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
Celgene

Completed

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Canada, United States, Taiwan, France, Spain, Greece, Italy, Singapore, Tunisia
AdventHealth

Completed

22G FNA Needle vs. 22G ProCore Needle

Pancreatic Neoplasm

United States
University of Florida

Completed

Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury

Spinal Cord Injuries

United States
Inter-American Development Bank
Universidade Federal do Ceara; Municipal Secretary of Health, Fortaleza Brasil

Unknown

Evaluation of the Home Visiting Pilot Program on Early Childhood Outcomes in Fortaleza Brazil

Child Development
Yale University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Withdrawn

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

United States
Celgene

Active, not recruiting

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Neoplasms | Hematologic Malignancies | Hematologic Neoplasm

United Kingdom, United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Ann Arbor Stage I Small Lymphocytic Lymphoma | Ann Arbor Stage II Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia... and other conditions

United States
Hutchmed

Recruiting

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Pathologic Processes | Immune System Diseases | Autoimmune Diseases | Hematologic Diseases | Hemorrhage | Hemorrhagic Disorders | Thrombotic Microangiopathies | Purpura | Purpura, Thrombocytopenic | Skin Manifestations | Thrombocytopenia | Purpura, Thrombocytopenic, Idiopathic | Immune Thrombocytopenia | Blood Coagulation... and other conditions

United States, Spain, Germany, Australia, Norway
AbbVie

Recruiting

A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants

Facial Volume Deficit

Germany, Spain
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase 2 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Advanced Solid Tumors Harboring NTRK Fusion | Primary Central Nervous System Tumors Harboring NTRK Fusion

China
ICM Co. Ltd.

Not yet recruiting

A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.

Osteoarthritis, Knee
Peel Therapeutics Inc

Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Solid Tumors

China
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

Chronic Spontaneous Urticaria
InnoCare Pharma Inc.

Active, not recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Aptose Biosciences Inc.

Terminated

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Acute Myelogenous Leukemia | Acute Myelogenous Leukemia in Relapse | Acute Myelogenous Leukemia, Relapsed, Adult | Acute Myelogenous Leukemia, Adult | High Risk Myelodysplasia

United States
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Solid Tumors

Australia, New Zealand
BioMed Valley Discoveries, Inc

Completed

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Advanced Solid Tumors

United States
BioMed Valley Discoveries, Inc

Completed

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Avanir Pharmaceuticals

Completed

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Multiple Sclerosis

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

Osteoarthritis | Healthy Subjects

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 in Healthy Japanese Males

Healthy

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Menopause

Belgium, Finland, Sweden, South Africa, Croatia, United Kingdom, France, Romania, Ukraine, Spain, Poland, Hungary, Czech Republic, Mexico, Netherlands
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluation LXR-623 in Healthy Adults

Healthy Subjects
M.D. Anderson Cancer Center

Active, not recruiting

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Lymphomas | B-cell Lymphomas

United States
Neuron23 Inc.

Terminated

A Study to Assess NEU-723 in Healthy Participants

Healthy

New Zealand
Homology Medicines, Inc

Withdrawn

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

Mucopolysaccharidosis II

United States, Canada
Kartos Therapeutics, Inc.

Terminated

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer Recurrent

Germany, Spain, France, Australia, United States, Korea, Republic of, Hungary
Calithera Biosciences, Inc

Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Squamous Non-small-cell Lung Cancer | NFE2L2 Gene Mutation | Squamous Non-Small Cell Neoplasm of Lung

United States
TWi Biotechnology, Inc.

Completed

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

Inherited Epidermolysis Bullosa

Taiwan
Asahi Kasei Pharma Corporation

Completed

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Japan
The Affiliated Hospital of the Chinese Academy...

Unknown

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

Leukemia, Myeloid, Acute

China
GE Healthcare

Completed

Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

Congestive Heart Failure

United States
Genus Oncology, LLC

Completed

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

Solid Tumors

United States
4SC AG

Completed

Single Dose Study With 4SC-203 in Healthy Volunteers

Acute Myeloid Leukemia

Germany
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Vasomotor Symptoms

United States
iTeos Belgium SA
Bristol-Myers Squibb; GlaxoSmithKline; iTeos Therapeutics

Terminated

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, France, Spain, Belgium
Mayo Clinic
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

Smoking

Japan

Search clinical trials for: CC-223

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations